George A. Eldridge - Nov 23, 2022 Form 4 Insider Report for Aerovate Therapeutics, Inc. (AVTE)

Role
Officer Title: Chief Financial Officer and Treasurer
Signature
/s/ George A. Eldridge
Stock symbol
AVTE
Transactions as of
Nov 23, 2022
Transactions value $
-$21,350
Form type
4
Date filed
11/28/2022, 04:00 PM
Previous filing
Nov 22, 2022
Next filing
Dec 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Options Exercise $2.7K +1.26K +64.34% $2.14* 3.22K Nov 23, 2022 Direct F1
transaction AVTE Common Stock Sale -$24K -1.26K -39.15% $19.07 1.96K Nov 23, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -1.26K -1.29% $0.00 96.4K Nov 23, 2022 Common Stock 1.26K $2.14 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.40, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 A total of 98,676 shares subject to an employee stock option were granted on April 1, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Remarks:

Officer Title: Chief Financial Officer and Treasurer